TScan Therapeutics is cutting its workforce by approximately 75% to prioritize its in vivo solid tumor program. The company is currently advancing two product candidates toward IND-enabling studies.
Management paused enrollment in the Phase 3 ALLOHA-2 study of TSC-101 for blood cancers due to insufficient capital. TScan will continue monitoring patients already enrolled in its hematologic malignancy studies.
This restructuring aims to extend the company’s cash runway into the fourth quarter of 2027. TScan is actively seeking strategic partnerships for its heme and autoimmune programs.
The company also reported updated positive data from its Phase 1 ALLOHA study.